Loading clinical trials...
Loading clinical trials...
Study the Safety and Efficacy of Human Umbilical Cord-derived Mesenchymal Stem Cells in the Treatment of Acute Cerebral Infarction
The purposes of the study is to determine the safety and efficacy of treating acute ischemic stroke patients with human umbilical cord mesenchymal stem cells (hUC-MSC).
This is a randomized, double-blind, paralleled study. 40 patients will be separated into two groups, and receive basic treatment (Aspirin Tablet). Patients in experimental group will receive hUC-MSC once a month, total 3 times. After the treatment, investigator will have follow-up visit for 6 months, evaluate the security and efficacy of hUC-MSC.
Age
40 - 75 years
Sex
ALL
Healthy Volunteers
No
Inner Mongolia International Mongolian Hospital
Hohhot, Inner Mongolia, China
Start Date
December 31, 2025
Primary Completion Date
June 30, 2026
Completion Date
December 31, 2026
Last Updated
May 14, 2025
40
ESTIMATED participants
Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#)
BIOLOGICAL
Aspirin Tablet
DRUG
Lead Sponsor
Sclnow Biotechnology Co., Ltd.
NCT06757764
NCT07140406
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07121088